Ayuna Jombik

Ayuna Jombik

Auto-generated profile, based on publicly available information

Ayuna Jombik

Kura Oncology, Inc., San Diego, California

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2026 in Cancer Research
Verified
Journal Article
Open access
PDF file
HPHetika Vora. Patel
Hetika Vora. Patel
ASAlison Elizabeth. Smith
Alison Elizabeth. Smith
SCStacia Chan
Stacia Chan
JGJovylyn Gatchalian. Gasendo
Jovylyn Gatchalian. Gasendo
AJAyuna Jombik
Ayuna Jombik
SMShivani Oncology Kura Malik
Shivani Oncology Kura Malik
Resistance remains a key issue limiting the clinical benefit from RAS-targeting therapeutic agents and necessitates combination approaches. In this study, we identified persistent mTORC1 activity in preclinical KRAS-mutant non–small cell lung cancer (NSCLC) and colorectal cancer models as a frequent, nongenetic driver of inherent and adaptive resistance to RAS inhibition. This vulnerability was targetable with the farnesyl transferase inhibitor darlifarnib (KO-2806), which blocks mTORC1 activation via RHEB while sparing mTORC2 to limit associated toxicities. The addition of KO-2806 to NSCLC or colorectal cancer tumors progressing on mutant-selective RAS inhibitors led to rapid and durable tumor regression. In contrast, switching from mutant-selective to pan-RAS inhibitor monotherapy resulted in only stasis of NSCLC tumors and had no effect on colorectal cancer tumor progression. Furthermore, the addition of KO-2806 rescued sensitivity of progressing tumors to the pan-RAS inhibitor RMC-6236. These results establish mTORC1 as an important mediator of escape from RAS inhibition and highlight KO-2806 as a promising RAS companion inhibitor in patients with prior RAS inhibitor exposure. Significance: KO-2806 salvages RAS inhibitor activity by controlling parallel mTORC1 in RAS inhibitor-resistant tumors in which vertical inhibition of MAPK is insufficient to restore sensitivity, providing a combination strategy for resistant patients.

17 June 2026
Verified
Other
Open access
PDF file
HPHetika Vora Patel
Hetika Vora Patel
ASAlison Elizabeth Smith
Alison Elizabeth Smith
SCStacia Chan
Stacia Chan
JGJovylyn Gatchalian Gasendo
Jovylyn Gatchalian Gasendo
AJAyuna Jombik
Ayuna Jombik
SMShivani Oncology Kura Malik
Shivani Oncology Kura Malik
Antitumor efficacy and tolerability of combined KO-2806 and MRTX1133 or RMC-6236 in KRAS-mutant CRC xenograft models.

17 June 2026
Verified
Other
Open access
PDF file
HPHetika Vora Patel
Hetika Vora Patel
ASAlison Elizabeth Smith
Alison Elizabeth Smith
SCStacia Chan
Stacia Chan
JGJovylyn Gatchalian Gasendo
Jovylyn Gatchalian Gasendo
AJAyuna Jombik
Ayuna Jombik
SMShivani Oncology Kura Malik
Shivani Oncology Kura Malik
Antitumor efficacy and tolerability of combined adagrasib and KO-2806 in KRASG12C-mutant NSCLC xenograft models.

17 June 2026
Verified
Other
Open access
HPHetika Vora Patel
Hetika Vora Patel
ASAlison Elizabeth Smith
Alison Elizabeth Smith
SCStacia Chan
Stacia Chan
JGJovylyn Gatchalian Gasendo
Jovylyn Gatchalian Gasendo
AJAyuna Jombik
Ayuna Jombik
SMShivani Oncology Kura Malik
Shivani Oncology Kura Malik
Intermittent dosing of KO-2806 leads to tumor regressions in combination with RAS inhibitors.

17 June 2026
Verified
Other
Open access
HPHetika Vora Patel
Hetika Vora Patel
ASAlison Elizabeth Smith
Alison Elizabeth Smith
SCStacia Chan
Stacia Chan
JGJovylyn Gatchalian Gasendo
Jovylyn Gatchalian Gasendo
AJAyuna Jombik
Ayuna Jombik
SMShivani Oncology Kura Malik
Shivani Oncology Kura Malik
Comparison of the physiochemical, metabolic, distribution, and pharmacokinetic properties of KO-2806 and the first-generation FTI tipifarnib.

17 June 2026
Verified
Other
Open access
PDF file
HPHetika Vora Patel
Hetika Vora Patel
ASAlison Elizabeth Smith
Alison Elizabeth Smith
SCStacia Chan
Stacia Chan
JGJovylyn Gatchalian Gasendo
Jovylyn Gatchalian Gasendo
AJAyuna Jombik
Ayuna Jombik
SMShivani Oncology Kura Malik
Shivani Oncology Kura Malik
Combination of KO-2806 and adagrasib inhibits mTOR signaling and induces tumor regression in KRASG12C-mutant NSCLC models